Hematologic Malignancy
Acute Leukemia
CI-CAN-00000399Explore in graph →
Hematologic1,259 active trials30 approved drugs323 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000399Explore in graph →
Clinical trials
4,653 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (718)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06301425 | MRD Response-adapted Allo-HSCT for Adverse-risk AML | recruiting | N/A | 178 | Peking University People's HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT05029531 | Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021) | recruiting | Phase 3 | 80 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jun 28, 2024 |
| clinicaltrials |
| NCT04968015 | Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission(LAMSA2020) | active not recruiting | Phase 2 | 134 | French Innovative Leukemia OrganisationOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06477549 | BeFluBu vs FluBuRux Conditioning in Haploidentical HCT | recruiting | Phase 2 | 220 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT05772559 | Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies(ALARM3) | recruiting | — | 500 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06463327 | ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML(ACHIEVE2) | not yet recruiting | Phase 1 | 69 | TC BiopharmINDUSTRY | 0 | Jun 17, 2024 | clinicaltrials |
| NCT05811845 | Mercaptopurine Therapeutic Drug Monitoring to Optimize the Maintenance Phase of Childhood ALL | recruiting | — | 250 | IRCCS Burlo GarofoloOTHER | 1 | Jun 14, 2024 | clinicaltrials |
| NCT06445803 | CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL | recruiting | Phase 1 | 48 | Rong TaoOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT06297772 | Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR | not yet recruiting | Phase 3 | 220 | Ruijin HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06441084 | A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation | not yet recruiting | Phase 1 | 15 | Nuwacell Biotechnologies Co., Ltd.INDUSTRY | 0 | Jun 4, 2024 | clinicaltrials |
| NCT04905810 | Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure | recruiting | Phase 2 | 20 | Brian JonasOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05310591 | Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence(CAPTiRALL) | recruiting | Phase 1 / Phase 2 | 26 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05326919 | The Patient Cohort of the National Center for Precision Medicine in Leukemia(eTHEMA) | recruiting | — | 3,000 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05580861 | Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment(SALMA) | recruiting | Phase 1 / Phase 2 | 64 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06225128 | Dynamics of Resistance Emergence to Azacitidine-based Therapies in Acute Myeloid Leukemia(DREAM) | recruiting | — | 120 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06418776 | IMPACT-AML: Randomized Pragmatic Clinical Trial for Relapsed or Refractory AML | recruiting | Phase 3 | 198 | National Research Center for Hematology, RussiaNETWORK | 1 | May 17, 2024 | clinicaltrials |
| NCT06410833 | Belimumab After Rituximab in Resistant Primary Juvenile SS(BRRPJS) | recruiting | Phase 4 | 15 | Peking Union Medical College HospitalOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06346912 | CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL | recruiting | Early Phase 1 | 20 | Zhejiang UniversityOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT06387420 | A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia | not yet recruiting | Phase 1 / Phase 2 | 180 | AkesoINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT06381817 | Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients | recruiting | Phase 3 | 146 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06385808 | Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML | not yet recruiting | N/A | 37 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Apr 26, 2024 | clinicaltrials |
| NCT03999723 | Combining Active and Passive DNA Hypomethylation(EVI-3) | recruiting | Phase 2 | 196 | Kirsten GrønbækOTHER | 2 | Apr 17, 2024 | clinicaltrials |
| NCT04793919 | Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia | recruiting | Phase 2 | 89 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 12 | Apr 15, 2024 | clinicaltrials |
| NCT06090786 | Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax | not yet recruiting | N/A | 225 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 0 | Apr 10, 2024 | clinicaltrials |
| NCT06206174 | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies | recruiting | Phase 1 / Phase 2 | 30 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06345365 | MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | recruiting | Phase 3 | 154 | Zhongnan HospitalOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT05319249 | Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia(NAKIP-AML) | not yet recruiting | Phase 1 / Phase 2 | 54 | German Cancer Research CenterOTHER | 0 | Apr 5, 2024 | clinicaltrials |
| NCT06250959 | RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.(BEAT-ALL-2024) | recruiting | Phase 2 | 124 | Chen SuningOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT06347458 | BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children | not yet recruiting | Phase 1 | 24 | Guangzhou Bio-gene Technology Co., LtdINDUSTRY | 0 | Apr 4, 2024 | clinicaltrials |
| NCT06329999 | A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML | recruiting | N/A | 78 | Ruijin HospitalOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06328179 | Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. | recruiting | N/A | 34 | Huai'an First People's HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT04243785 | A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | recruiting | Phase 1 | 80 | Edgewood Oncology Inc.INDUSTRY | 1 | Mar 20, 2024 | clinicaltrials |
| NCT01686334 | Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission(WIDEA) | active not recruiting | Phase 2 | 130 | Zwi BernemanOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06295029 | Personalized Medication Software for BCL-2 Inhibitor in AML Patients Using Machine Learning and Genomics | not yet recruiting | — | 200 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Mar 6, 2024 | clinicaltrials |
| NCT06046313 | Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS | recruiting | Phase 2 | 120 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06050941 | Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS | not yet recruiting | Phase 2 | 60 | First Affiliated Hospital of Zhejiang UniversityOTHER | 0 | Mar 5, 2024 | clinicaltrials |
| NCT06256627 | The Maintenance Treatment of "ITIVA" in AML Patients | recruiting | N/A | 130 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06252584 | Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients(AML-VAC-XS15) | not yet recruiting | Phase 1 | 20 | University Hospital TuebingenOTHER | 0 | Feb 9, 2024 | clinicaltrials |
| NCT06242353 | Coagulopathy in Childhood Acute Lymphoblastic Leukaemia(CoagCALL) | not yet recruiting | — | 100 | Karolinska University HospitalOTHER | 0 | Feb 5, 2024 | clinicaltrials |
| NCT06237192 | MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients | recruiting | N/A | 200 | National Research Center for Hematology, RussiaNETWORK | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06232694 | Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML | recruiting | N/A | 54 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06220487 | A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL(ABC) | recruiting | Phase 2 | 67 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06175923 | Role of BMP Pathway in MDS Progression(BMP-MDS) | not yet recruiting | — | 60 | Hospices Civils de LyonOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06211166 | Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction | recruiting | — | 300 | Peking University People's HospitalOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT04105530 | Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL) | active not recruiting | N/A | 36 | St. Jude Children's Research HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT04897490 | RWE of 1st Line Treatment With ATO/ATRA for Adult APL | recruiting | — | 50 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05127148 | RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL | recruiting | — | 100 | Grupo Argentino de Tratamiento de la Leucemia AgudaOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05839392 | Novel Approaches to Target MECOM/EVI1 in AML | recruiting | N/A | 24 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Dec 29, 2023 | clinicaltrials |
| NCT06175702 | Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL(LALPh2022) | not yet recruiting | — | 150 | PETHEMA FoundationOTHER | 0 | Dec 19, 2023 | clinicaltrials |
| NCT06136364 | CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study | recruiting | Phase 1 | 9 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Jul 10, 2024source: clinicaltrials